Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas
RNA whole-transcriptome sequencing test informs thyroid cancer treatment decisions at time of diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 11, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of new data demonstrating the clinical and analytical validity of its
View HTML
Toggle Summary Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer
Data support use of Afirma Xpression Atlas to inform surgery and treatment decisions at time of diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 3, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of new data that further define the genomic landscape around thyroid
View HTML

Events

There are currently no events to display.

Presentations

Title Documents

Corporate Presentation August 2019